Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Medula
Asep Sukohar
Medical Faculty of Lampung University
Education Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Tatalaksana Aritmia: Fibrilasi Atrial Gede Agus Andika; Asep Sukohar; Ade Yonata
Medula Vol 11 No 3 (2021): Medula
Publisher : CV. Jasa Sukses Abadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53089/medula.v11i3.309

Abstract

Abstract Arrhythmias are a problem with the rate or rhythm of the heartbeat. The four main types of arrhythmias are premature or premature beats, ventricular arrhythmias, bradiarimia, and supraventricular arrhythmias. Supraventricular arrhythmias are tachycardia (rapid heartbeat) starting at the atrial or atrioventricular (AV). Types of supraventricular outbreaks include atrial fibrillation (AF), atrial flutter, paroxysmal supraventricular tachycardia (PSVT), and Wolff-Parkinson-White syndrome (WPW). Atrial fibrillation is the most common type of arrhythmia. In general, the management of AF patients has 5 objectives: thromboembolic events, coping with AF related symptoms, optimal management of accompanying cardiovascular disease, controlling heart rate, and improving rhythm disturbance. Antithrombotic therapy used for stroke prevention in FA patients includes anticoagulants (vitamin K or AVK antagonists and new anticoagulants or IMR), and antiplatelets. AKB which is not AVK in Indonesia market, that is dabigatran, rivaroxaban, and apixaban. Dabigatran works by dealing directly with trombinlah rivaroxaban and apixabanacas works by presenting the Xa factor.
the Perkembangan dalam Penatalaksanaan Covid-19 F Dea Chika; Asep Sukohar
Medula Vol 11 No 2 (2021): Medula
Publisher : CV. Jasa Sukses Abadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53089/medula.v11i2.312

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts are ongoing for clinical trials of several known antiviral drugs, their combination, as well as development of vaccines in patients with confirmed COVID-19. This review focuses on the latest approaches to diagnostics and therapy of COVID-19. We have summarized recent progress on the conventional therapeutics such as antiviral drugs, vaccines, anti-SARS-CoV-2 antibody treatments, and convalescent plasma therapy which are currently under extensive research and clinical trials for the treatment of COVID-19. The developments of nanoparticle-based therapeutic and diagnostic approaches have been also discussed for COVID-19. We have assessed recent literature data on this topic and made a summary of current development and future perspectives.
Co-Authors Ade Yonata F Dea Chika Gede Agus Andika